At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
In Brief
A Phase 2 clinical trial evaluating bevacizumab, trastuzumab, and 2 other interventions for Esophageal Cancer and Gastric Cancer. Completed, enrolled 37 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy, capecitabine and oxaliplatin, plus the antibodies bevacizumab and trastuzumab. Trastuzumab (also called Herceptin) is an antibody that attacks HER2 protein in tumor cells. Bevacizumab (also called Avastin) works by slowing or stopping the growth of cells in cancer tumors by decreasing the blood supply of the tumors. If blood supply is decreased, oxygen and nutrients that are needed for tumor growth are decreased. The chemotherapy used in this trial is called CAPOX, which is an abbreviation of capecitabine and oxaliplatin.
Study Details
Timeline
Interventions
Given intravenously on day 1 of each cycle beginning cycle 2
Given intravenously on day 1 of each treatment cycle
Given intravenously on day one of each cycle beginning cycle 2
Taken orally on days 1-14 of each cycle beginning cycle 2